文献速递甲状腺疾病

靶向线粒体相关ACC2调控BRAFV600E甲状腺乳头状癌脂质代谢

Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in BRAFV600E Papillary Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2021-03-03

该研究在TCGA甲状腺乳头状癌(PTC)样本中行RNA-seq与DNA拷贝数分析,并在不同BRAF状态PTC细胞系及BRAFWT/V600E异种移植小鼠模型中验证。结果显示BRAFV600E下调ACC2,维莫非尼以等位基因剂量依赖方式升高ACC2 mRNA并改变脂质合成与脂肪酸氧化;敲低ACC2可协同维莫非尼增加活性氧、促增殖并导致耐药与肿瘤生长。

要点

  • BRAFV600E下调PTC中ACC2表达,扰乱新生脂质合成与脂肪酸氧化。
  • 维莫非尼以BRAFV600E等位基因剂量依赖方式上调ACC2(对ACC1作用较弱)。
  • 敲低ACC2协同维莫非尼增加活性氧并促耐药与肿瘤生长,ACC2恢复或为克服耐药策略。

核心结论

  • BRAFV600E与PTC脂质代谢调控存在潜在联系,BRAFV600E下调ACC2并 deregulate 新生脂质合成、基于OCR的FAO与ECAR。
  • 敲低ACC2可能促进维莫非尼耐药与肿瘤生长,恢复ACC2或为克服BRAFV600E抑制剂耐药的新分子策略。

研究设计与样本

  • 对TCGA中PTC与正常甲状腺(NT)样本行RNA-seq与DNA拷贝数分析。
  • 在不同BRAF状态的PTC衍生细胞系及BRAFWT/V600E PTC细胞系(敲低ACC1或ACC2)异种移植小鼠模型中验证。

主要发现

  • ACC2 mRNA在BRAFV600E-PTC较BRAFWT-PTC或NT临床样本显著下调。
  • ACC2蛋白在BRAFV600E-PTC细胞系较BRAFWT/WT PTC细胞系下调。
  • 维莫非尼以BRAFV600E等位基因剂量依赖方式升高PTC细胞系ACC2(对ACC1作用较弱)mRNA。
  • 仅shACC2在BRAFV600E PTC细胞中较对照显著增加因FAO的OCR并降低ECAR。
  • 维莫非尼抑制增加新生脂质合成速率,并降低加棕榈酸后的FAO(以OCR、ECAR评估)。

临床怎么用

  • 关注BRAFV600E PTC中ACC2下调对脂质代谢与维莫非尼耐药的影响。
  • ACC2或可作为克服BRAFV600E抑制剂耐药的潜在分子靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: BRAFV600E acts as an ATP-dependent cytosolic kinase. BRAFV600E inhibitors are widely available, but resistance to them is widely reported in the clinic. Lipid metabolism (fatty acids) is fundamental for energy and to control cell stress. Whether and how BRAFV600E impacts lipid metabolism regulation in papillary thyroid carcinoma (PTC) is still unknown. Acetyl-CoA carboxylase (ACC) is a rate-limiting enzyme for de novo lipid synthesis and inhibition of fatty acid oxidation (FAO). ACC1 and ACC2 genes encode distinct isoforms of ACC. The aim of our study was to determine the relationship between BRAFV600E and ACC in PTC. Methods: We performed RNA-seq and DNA copy number analyses in PTC and normal thyroid (NT) in The Cancer Genome Atlas samples. Validations were performed by using assays on PTC-derived cell lines of differing BRAF status and a xenograft mouse model derived from a heterozygous BRAFWT/V600E PTC-derived cell line with knockdown (sh) of ACC1 or ACC2. Results:ACC2 mRNA expression was significantly downregulated in BRAFV600E-PTC vs. BRAFWT-PTC or NT clinical samples. ACC2 protein levels were downregulated in BRAFV600E-PTC cell lines vs. the BRAFWT/WT PTC cell line. Vemurafenib increased ACC2 (and to a lesser extent ACC1) mRNA levels in PTC-derived cell lines in a BRAFV600E allelic dose-dependent manner. BRAFV600E inhibition increased de novo lipid synthesis rates, and decreased FAO due to oxygen consumption rate (OCR), and extracellular acidification rate (ECAR), after addition of palmitate. Only shACC2 significantly increased OCR rates due to FAO, while it decreased ECAR in BRAFV600E PTC-derived cells vs. controls. BRAFV600E inhibition synergized with shACC2 to increase intracellular reactive oxygen species production, leading to increased cell proliferation and, ultimately, vemurafenib resistance. Mice implanted with a BRAFWT/V600E PTC-derived cell line with shACC2 showed significantly increased tumor growth after vemurafenib treatment, while vehicle-treated controls, or shGFP control cells treated with vemurafenib showed stable tumor growth. Conclusions: These findings suggest a potential link between BRAFV600E and lipid metabolism regulation in PTC. BRAFV600E downregulates ACC2 levels, which deregulates de novo lipid synthesis, FAO due to OCR, and ECAR rates. ShACC2 may contribute to vemurafenib resistance and increased tumor growth. ACC2 rescue may represent a novel molecular strategy for overcoming resistance to BRAFV600E inhibitors in refractory PTC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Valvo V, Iesato A, Kavanagh TR, et al. Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in BRAFV600E Papillary Thyroid Carcinoma. Thyroid. 2021. PMID: 33107403. doi:10.1089/thy.2020.0311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。